CAS: 871026-44-7; N-(2-(4-((3-Chloro-4-(3-(Trifluoromethyl)Phenoxy)Phenyl)Amino)-5H-Pyrrolo[3,2-D]Pyrimidin-5-yl)Ethyl)-3-Hydroxy-3-Methylbutanamide
该化合物是一个小分子,主要作为某些受体强氧素运动酶的选择性抑制器,特别是那些参与癌症信号路径的受体强氧素运动,其特点是能够干扰对细胞扩散和存活至关重要的磷酸化过程,使其成为癌症研究和治疗发展的一个主题.TAK-285展示了目标血脉系的具体结合,这可能导致各种癌症模型抑制肿瘤生长.该化合物通常在其药用动力学,功效和安全特征及其在定向癌症治疗中的潜在应用方面进行研究.此外,其化学结构还包括有助于其生物活动和溶性功能组.与许多研究药物一样,正在进行的研究旨在阐明其全部治疗潜力和肿瘤行动机制.
- 英文名称N-(2-(4-((3-Chloro-4-(3-(Trifluoromethyl)Phenoxy)Phenyl)Amino)-5H-Pyrrolo[3,2-D]Pyrimidin-5-yl)Ethyl)-3-Hydroxy-3-Methylbutanamide
- 中文名称TAK 285; N-[2-[4-[[3-氯-4-[3-(三氟甲基)苯氧基]苯基]氨基]-5H-吡咯并[3,2-d]嘧啶-5-基]乙基]-3-羟基-3-甲基丁酰胺
- IUPAC名称N-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide
- CAS编号871026-44-7
- MFCD编号:MFCD22124520
- FDA UNII编号:70CCB438L6
- 分子式:C26H25ClF3N5O3分子量:547.97
- 产品CID: 1876058
- 产品分类生物化工 → 抑制剂 → 蛋白酪氨酸激酶
物理性质
- 熔点167-169°C
- 沸点705.5±60.0 °C(预测)
- 密度1.39
- pKa:14.56±0.29(预测)
- PSA:104.79
- LogP:6.8299
- 溶解性≥27.4 mg/mL In DMSO; Insoluble In H2O; Insoluble In Etoh
- 外观形态白色至淡黄色固体
- 储存条件储存在 -20°C
- 产品应用该化合物是HER2和EGFR(HER1)的新型双重抑制器,IC50值分别为17纳米和23纳米;HER1/2比HER4有十倍以上的选择性,而MER4比H1/2有十多倍的选择性,MEC1/5,C-MET,AURORA B,LCK,CSK和LYNB的活动较弱;它严重抑制HER2-超常表达BT-474人类乳腺癌细胞的生长(GI50=17纳米);在体外,它显示出HER-2超常表现BT-474和4-1ST(人类胃癌)鼠标模型以及4-1-ST老鼠肿瘤模型的抗菌功效,这些模型依赖剂量的肿瘤生长抑制和回归,而没有重大体重损失;目前处于第一阶段临床试验阶段.
上下游产品
3-Hydroxy-3-methylbutyric acid tert-butyl [2-(4-chloro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethyl]carbamate 3-chloro-4-fluoronitrobenzene 3-Trifluoromethylphenol合成工艺路线路线简述
- 625-08-1 + 871084-93-4 = 871026-44-7
反应条件:1.1 Reagents: Triethylamine,1-Hydroxybenzotriazole,1-Ethyl-3-(3′-Dimethylaminopropyl)Carbodiimide Hydrochloride Solvents: Dimethylformamide; 3 D,Rt
标题:Design And Synthesis Of Novel Human Epidermal Growth Factor Receptor 2 (Her2)/epidermal Growth Factor Receptor (Egfr) Dual Inhibitors Bearing A Pyrrolo[3,2-D]Pyrimidine Scaffold
作者:Ishikawa,Tomoyasu; Et Al
参考文献:Journal Of Medicinal Chemistry 日期:2011 卷标:54(23) 页码:8030-8050]
350-30-1 + 98-17-9 = 871026-44-7
反应条件:1.1 Reagents: Potassium Carbonate Solvents: Dimethylformamide; 2 H,80 °C1.2 Reagents: Hydrogen Catalysts: Platinum Solvents: Ethyl Acetate; 2 H,Rt2.1 Solvents: Isopropanol; 12 H,80 °C2.2 Reagents: Sodium Bicarbonate Solvents: Water; Cooled3.1 Reagents: Hydrochloric Acid Solvents: Tetrahydrofuran,Water; 20 H,60 °C4.1 Reagents: Triethylamine,1-Hydroxybenzotriazole,1-Ethyl-3-(3′-Dimethylaminopropyl)Carbodiimide Hydrochloride Solvents: Dimethylformamide; 3 D,Rt
标题:Design And Synthesis Of Novel Human Epidermal Growth Factor Receptor 2 (Her2)/epidermal Growth Factor Receptor (Egfr) Dual Inhibitors Bearing A Pyrrolo[3,2-D]Pyrimidine Scaffold
作者:Ishikawa,Tomoyasu; Et Al
参考文献:Journal Of Medicinal Chemistry 日期:2011 卷标:54(23) 页码:8030-8050]
871026-38-9 = 871026-44-7
反应条件:1.1 Reagents: Hydrochloric Acid Solvents: Tetrahydrofuran,Water; 20 H,60 °C2.1 Reagents: Triethylamine,1-Hydroxybenzotriazole,1-Ethyl-3-(3′-Dimethylaminopropyl)Carbodiimide Hydrochloride Solvents: Dimethylformamide; 3 D,Rt
标题:Design And Synthesis Of Novel Human Epidermal Growth Factor Receptor 2 (Her2)/epidermal Growth Factor Receptor (Egfr) Dual Inhibitors Bearing A Pyrrolo[3,2-D]Pyrimidine Scaffold
作者:Ishikawa,Tomoyasu; Et Al
参考文献:Journal Of Medicinal Chemistry 日期:2011 卷标:54(23) 页码:8030-8050]
871026-37-8 + 40718-14-7 = 871026-44-7
反应条件:1.1 Solvents: Isopropanol; 12 H,80 °C1.2 Reagents: Sodium Bicarbonate Solvents: Water; Cooled2.1 Reagents: Hydrochloric Acid Solvents: Tetrahydrofuran,Water; 20 H,60 °C3.1 Reagents: Triethylamine,1-Hydroxybenzotriazole,1-Ethyl-3-(3′-Dimethylaminopropyl)Carbodiimide Hydrochloride Solvents: Dimethylformamide; 3 D,Rt
标题:Design And Synthesis Of Novel Human Epidermal Growth Factor Receptor 2 (Her2)/epidermal Growth Factor Receptor (Egfr) Dual Inhibitors Bearing A Pyrrolo[3,2-D]Pyrimidine Scaffold
作者:Ishikawa,Tomoyasu; Et Al
参考文献:Journal Of Medicinal Chemistry 日期:2011 卷标:54(23) 页码:8030-8050]
84905-80-6 + 39684-80-5 = 871026-44-7
反应条件:1.1 Reagents: Cesium Carbonate Solvents: Dimethylformamide; 4 D,40 °C2.1 Solvents: Isopropanol; 12 H,80 °C2.2 Reagents: Sodium Bicarbonate Solvents: Water; Cooled3.1 Reagents: Hydrochloric Acid Solvents: Tetrahydrofuran,Water; 20 H,60 °C4.1 Reagents: Triethylamine,1-Hydroxybenzotriazole,1-Ethyl-3-(3′-Dimethylaminopropyl)Carbodiimide Hydrochloride Solvents: Dimethylformamide; 3 D,Rt
标题:Design And Synthesis Of Novel Human Epidermal Growth Factor Receptor 2 (Her2)/epidermal Growth Factor Receptor (Egfr) Dual Inhibitors Bearing A Pyrrolo[3,2-D]Pyrimidine Scaffold
作者:Ishikawa,Tomoyasu; Et Al
参考文献:Journal Of Medicinal Chemistry 日期:2011 卷标:54(23) 页码:8030-8050
📜3-氯-4-(3-三氟甲基-苯氧基)-苯胺置于盐酸,1-羟基苯并三唑,盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺,三乙胺体系中,用 四氢呋喃,水,N,N-二甲基甲酰胺,异丙醇 作为反应溶剂,化学反应 104.0H,反应生成 Tak 285; N-[2-[4-[[3-氯-4-[3-(三氟甲基)苯氧基]苯基]氨基]-5H-吡咯并[3,2-D]嘧啶-5-基]乙基]-3-羟基-3-甲基丁酰胺
参考文献:新型人表皮生长因子受体2(her2)/表皮生长因子受体(egfr)双重抑制剂带有吡咯并[3,2-D]嘧啶骨架的设计与合成
标题:新型人表皮生长因子受体2(her2)/表皮生长因子受体(egfr)双重抑制剂带有吡咯并[3,2-D]嘧啶骨架的设计与合成
摘要:研发了人类表皮生长因子受体2(her2)和表皮生长因子受体(egfr)的双重抑制剂可治疗乳腺癌,肺癌,胃癌,前列腺癌和其他癌症.一种是拉帕替尼,目前已获准用于乳腺癌.为了开发新型的her2 / Egfr双激酶抑制剂,我们设计并合成了能够适合受体atp结合位点的吡咯并[3,2-D]嘧啶衍生物.在制备的化合物中,34E显示出有效的her2和egfr(her1)抑制活性以及肿瘤生长抑制活性.34E与her2和egfr的x射线共晶体结构表明34E与它们各自的atp口袋中的预期残基相互作用.此外,由于34E具有非常好的口服生物利用度,因此在过表达her2的肿瘤异种移植模型中显示出强大的体内功效.基于这些发现,我们报道34E(tak-285)作为一种新型her2 / Egfr双激酶抑制剂在临床开发中很有希望.
DOI:10.1021/jm2008634
海关参考信息
- 2902300000-甲苯
2903919090-氯苯
2905122000-异丙醇
2905143000-叔丁醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-11406709-B2
优先权日:2014-09-15
标 题 :Therapeutic and research application of PDCL3
发明人：RAHIMI NADER
权利人:UNIV BOSTON
摘要:Described herein are novel compositions comprising, for example, PDCL3 polypeptides having VEGFR-2 inhibitory activity, inhibitory PDCL3 antibodies and PDCL3-binding fragments thereof, or PDCL3 inhibitory nucleic acid molecules, and methods of their use in anti-angiogenesis and anti-tumor proliferation and invasiveness therapies, such as the treatment of cancer, as well as the treatment of those vascular diseases where pathological angiogenesis plays a role, such as in carotid artery disease, macular degeneration, and plaque neovascularization. Also described herein are novel compositions comprising engineered PDCL3 polypeptides having enhanced chaperone activity, recombinant cells comprising such engineered PDCL3 polypeptides having enhanced chaperone activity, and methods thereof for therapeutic protein production and in vitro protein synthesis.
专利号:US-2022396794-A1
优先权日:2019-06-04
标题:APTAMERS AGAINST TRANSFERRIN RECEPTOR (TfR)
发明人：HABIB NAGY; ROSSI JOHN; YOON SORAH; SWIDERSK PIOTR MAREK
权利人:APTERNA LTD; HOPE CITY
摘要:Methods of treating or preventing a disease or disorder are disclosed comprising administering to a subject in need thereof an effective amount of a nucleic acid compound comprising, or consisting of, a nucleic acid sequence capable of binding to a transferrin receptor (TfR) and an effective amount of an inhibitor of DNA synthesis. Also disclosed is a nucleic acid compound comprising, or consisting of, a nucleic acid sequence having at least 85% sequence identity to SEQ ID NO: 1, wherein said nucleic acid sequence is at least 30 nucleotides in length and at most 50 nucleotides in length, and wherein the nucleic acid sequence is capable of binding to a transferrin receptor (TfR).
专利号:WO-2023241290-A1
优先权日:2022-06-13
标 题:Pharmaceutical compound based on quinolizidine derivative, and preparation method therefor and use thereof
发明人：YIN XIAOYING; WANG YANQING; LIU QINGSHAN; SHAN HONGLI; TANG LI; CHEN LINGYAN
权利人:UNIV SHANGHAI ENG SCIENCE
摘要:The present invention relates to the technical field of anti-tumor and anti-nerve-injury drug synthesis. Disclosed are an anti-tumor and anti-nerve-injury pharmaceutical compound based on a quinolizidine derivative, a use and a preparation method. Compared with the prior art, in the structural formula of the pharmaceutical compound provided by the present application, based on a natural quinolizidine alkaloid-isoflavone skeleton, structural modification is performed on an isoflavone part to obtain a series of derivatives, and experiments prove that the series of compounds can resist nerve injury, and has good application prospects in the aspect of preventing and treating nerve injury related diseases, wherein R2=R3=H; when R2 and R3 are functional groups which easily form a hydrogen bond, the series of compounds have anti-tumor activity and have application prospects. The present invention has the advantages that the preparation method is efficient and easy to operate, and the product has high purity and high activity.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Ishikawa T, Seto M, Banno H, Kawakita Y, Oorui M, Taniguchi T, Ohta Y, Tamura T, Nakayama A, Miki H, Kamiguchi H, Tanaka T, Habuka N, Sogabe S, Yano J, Aertgeerts K, Kamiyama K. Design and Synthesis of Novel Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors Bearing a Pyrrolo[3,2-d]pyrimidine Scaffold. J Med Chem. 2011 Nov 4. [Epub ahead of print]
合成参考文献
参考文献:10.1016/j.bmcl.2015.10.003
摘要:Elkamhawy A, Farag AK, Viswanath ANI, Bedair TM, Leem DG, Lee K, Pae AN, Roh EJ. Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking. Bioorganic & Medicinal Chemistry Letters. 2015 Nov;25(22):5147–54. doi: 10.1016/j.bmcl.2015.10.003.
📝 需求与反馈
尽可能描述清楚需求与问题信息
